Tetracyclines: Drugs with huge therapeutic potential

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 44-52

  Bahrami, F ^a   Morris, D L ^a   Pourgholami, M H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antibiotic; Apoptosis; Cytokines; Doxycycline; Inflammation; Matrix metalloproteinase; Minocycline; Neurodegenerative diseases; Stroke; Tetracyclines

Indexed keywords

ANTIINFLAMMATORY AGENT; CHLORTETRACYCLINE; CYTOKINE; DOXYCYCLINE; MATRIX METALLOPROTEINASE; MINOCYCLINE; NEUROPROTECTIVE AGENT; TETRACYCLINE; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CHLAMYDIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DRUG RESISTANCE; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; MENTAL DISEASE; REVIEW; RICKETTSIOSIS; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; VIRUS PNEUMONIA;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; NEUROPROTECTIVE AGENTS; TETRACYCLINES;

EID: 84855837524     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712798868977     Document Type: Review

References (76)

1. Michael O. G.; Eduardo F.; Guillermo C.; Francisco V. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell. Physiol., 2010, C539-C48.
2. Duggar B.M. Aureomycin: a product of the continuing search for new antibiotics. Ann. NY. Acad. Sci., 1948, 51, 177-81.
3. Ian Ch.; Marilyn R. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiol. Mol. Biol. Rev., 2001, 65, 232-60.
4. Zakeri B, W. G. Chemical biology of tetracycline antibiotics. Biochem. Cell Biol., 2008 Apr, 86, 124-36.
5. Stephens C. R.; Conover L. H.; Pasternack R.; Hochstein F. A.; Moreland W. T.; Regna P. P. The structure of aureomycin. J. Am. Chem. Soc., 1954, 76, 3568-75.
6. Smith, K.; Leyden, J. J. Safety of doxycycline and minocycline: a systematic review. Clin. Ther., 2005, 27, 1329-42.
7. George A. Pankey. Tigecycline. J. Antimicrobial Chemotherapy, 2005, 56, 470-80.
8. Smilack J. D. The tetracyclines. Mayo Clin. Proc., 1999, 74, 727-29.
9. Saikali Z; G., S. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs, 2003 14, 773-78.
10. Ochsendorf, F. Minocycline in acne vulgaris: benefits and risks. Am. J. Clin. Dermatol., 2010, 11, 327-41.
11. Kurokawa, I.; Danby, F. W.; Ju, Q.; Wang, X.; Xiang, L. F.; Xia, L.; Chen, W.; Nagy, I.; Picardo, M.; Suh, D. H.; Ganceviciene, R.; Schagen, S.; Tsatsou, F.; Zouboulis, C. C. New developments in our understanding of acne pathogenesis and treatment. Exp. Dermatol., 2009, 18, 821-32.
12. Maffeis, L.; Veraldi, S. Minocycline in the treatment of acne: latest findings. Ital. Dermatol. Venereol., 2010, 145, 425-9.
13. Kircik, L. H. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J. Drugs Dermatol., 2010, 9, 1407-11.
14. Webster, G. F.; Mcginley, K. J.; Leyden, J. J. Ihibition of lipase production in propionibacterium-acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br. J. Dermatol., 1981, 104, 453-57.
15. Roberts, G.; Capell, H. A. The Frequency and Distribution of Minocycline Induced Hyperpigmentation in a Rheumatoid Arthritis Population. J. Rheumatol. 2006, 33, 1254-57.
16. Gaggar, A.; Rowe, S. M.; Hardision, M.; Blalock, J. E. Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. Open Respir. Med. J., 2010, 4, 32-38.
17. Ian Ch.; P. M. H.; M. H. Tetracyclines, molecular and clinical aspects. Review. J. Antimicrobial Chemother., 1992, 29, 245-77.
18. Dirk S.; Wolfgang H. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch. Microbiol., 1996, 165, 359-69.
19. Joshi, N.; Debra Q. Miller. Doxycycline Revisited. Arch. Intern. Med., 1997 157, 1421-28.
20. Nelson M. L. Chemical and biological dynamics of tetracyclines. Adv. Dent. Res., 1998, 12, 5-11.
21. Michael B.; Richard B. B.; Carolyn Sh.; Charles G.; Louis W. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in Dogs. Antimicrob. Agents Chemother., 1975, 8, 713-20.
22. P.R. Ball; Shales, S. W.; Chopra, I. Plasmid-mediated tetracycline resistance in escherichia coli involves increased efflux of the antibiotic Biochem. Biophys. Res. Commun., 1980 93, 74-81.
23. Burdett V. Purification and characterization of Tet(M), a protein that renders ribosomes resistant to tetracycline. J. Biol. Chem., 1991 Feb, 266, 2872-77.
24. Yang W.; Moore I. F.; Koteva K. P.; Bareich D. C.; Hughes D. W.; D., W. G. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J. Biol. Chem., 2004, 279, 52346-52.
25. Ross, J. I.; Eady, E. A.; Cove, J. H.; Cunliffe, W. J. 16S rRNA Mutation Associated with Tetracycline Resistance in a Gram-Positive Bacterium. Antimicrob. Agents Chemother., 1998, 42, 1702-05.
26. Alexey A.; Thomas S. The Tetracycline:Mg2+ Complex: A Molecular Mechanics force Field. J. Comput. Chem., 2006, 27, 1517-33.
27. Phaik-Eng Sum; Adma T. Ross; Peter J. Petersenb; Raymond T. Testab. Synthesis and antibacterial activity of 9-substituted minocycline derivatives. Bioorg. Med. Chem. Lett., 2006, 16, 400-03.
28. Greenwald, R. A. Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines. Ann. N Y Acad. Sci., 1994, 732, 181-98.
29. Dorman, G.; Cseh, S.; Hajdu, I.; Barna, L.; Konya, D.; Kupai, K.; Kovacs, L.; Ferdinandy, P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs, 2010, 70, 949-64.
30. Tu G; Xu W; Huang H; S., L. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2008, 15, 1388-95.
31. Yoon, S. O.; Park, S. J.; Yun, C. H.; Chung, A. S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol., 2003, 36, 128-37.
32. Machado, L. S.; Sazonova, I. Y.; Kozak, A.; Wiley, D. C.; El-Remessy, A. B.; Ergul, A.; Hess, D. C.; Waller, J. L.; Fagan, S. C. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke, 2009, 40, 3028-33.
33. Ohshima, S.; Fujimoto, S.; Petrov, A.; Nakagami, H.; Haider, N.; Zhou, J.; Tahara, N.; Osako, M. K.; Fujimoto, A.; Zhu, J.; Murohara, T.; Edwards, D. S.; Narula, N.; Wong, N. D.; Chandrashekhar, Y.; Morishita, R.; Narula, J. Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging. J. Am. Coll. Cardiol., 2010, 55, 1240-9.
34. Rabadi, M. H.; Blass, J. P. Randomized clinical stroke trials in 2007. Open Neurol. J., 2008, 2, 55-65.
35. Arvelo, F.; Cotte, C. Metalloproteinases in tumor progression. Review. Invest. Clin., 2006, 47, 185-205.
36. Cao, J.; Chiarelli, C.; Kozarekar, P.; Adler, H. L. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb. Haemost., 2005, 93, 770-8.
37. Rooprai, H. K.; Rucklidge, G. J.; Panou, C.; Pilkington, G. J. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br. J. Cancer, 2000, 82, 52-5.
38. Bhadada, S. V.; Goyal, B. R.; Patel, M. M. Angiogenic targets for potential disorders. Fundam. Clin. Pharmacol., 2010, 25, 29-47.
39. Aggarwal, B. B.; Sethi, G.; Ahn, K. S.; Sandur, S. K.; Pandey, M. K.; Kunnumakkara, A. B.; Sung, B.; Ichikawa, H. Targeting signaltransducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N Y Acad. Sci., 2006, 1091, 151-69.
40. Yu L.; Maria E. R.; Hsi-Ming L.; Sanford S.; George T.; Carol L.; Michael K. L.; Lorne M. G. A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent. Antimicrob. Agents Chemother., 2002, 46, 1447-54.
41. Acharya, M. R.; Venitz, J.; Figg, W. D.; Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat., 2004, 7, 195-208.
42. Gaggar, A.; Jackson, P. L.; Noerager, B. D.; O'reilly, P. J.; Mcquaid, D. B.; Rowe, S. M.; Clancy, J. P.; Blalock, J. E. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol., 2008, 180, 5662-9.
43. Katrib, A.; Smith, M. D.; Ahern, M. J.; Slavotinek, J.; Stafford, L.; Cuello, C.; Bertouch, J. V.; Mcneil, H. P.; Youssef, P. P. Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission. J. Rheumatol., 2003, 30, 10-21.
44. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010, 141, 52-67.
45. Bernardino, A. L.; Kaushal, D.; Philipp, M. T. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis, 2009, 199, 1379-88.
46. Golub L. M.; Ramamurthy N. S.; Mcnamara T. F.; Greenwald R. A.; R., R. B. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med., 1991, 2, 297-321.
47. Daniela D.; P., G. J.; Alexey A.; Thomas S.; Winfried H. Nonantibiotic Properties of Tetracyclines: Structural Basis for Inhibition of Secretory Phospholipase A2. J. Mol. Biol., 2010, 398, 83-96.
48. Khanapure, S. P.; Garvey, D. S.; Janero, D. R.; Letts, L. G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem., 2007, 7, 311-40.
49. Pillai, S.; Oresajo, C.; Hayward, J. Ultraviolet radiation and skin aging: roles of reactive oxygen species, inflammation and protease activation, and strategies for prevention of inflammation-induced matrix degradation-a review. Int. J. Cosmet. Sci., 2005, 27, 17-34.
50. Garcia-Martinez, E. M.; Sanz-Blasco, S.; Karachitos, A.; Bandez, M. J.; Fernandez-Gomez, F. J.; Perez-Alvarez, S.; De Mera, R. M.; Jordan, M. J.; Aguirre, N.; Galindo, M. F.; Villalobos, C.; Navarro, A.; Kmita, H.; Jordan, J. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem. Pharmacol., 2010, 79, 239-50.
51. Shapira, L.; Soskolne, W. A.; Houri, Y.; Barak, V.; Halabi, A.; Stabholz, A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect. Immun., 1996, 64, 825-8.
52. Cazalis, J.; Bodet, C.; Gagnon, G.; Grenier, D. Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models. J. Periodontol., 2008, 79, 1762-8.
53. Jantzie, L. L.; Todd, K. G. Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats. J. Psychiatry Neurosci., 2010, 35, 20-32.
54. Mima, T.; Nishimoto, N. Clinical value of blocking IL-6 receptor. Curr. Opin. Rheumatol., 2009, 21, 224-30.
55. Pourgholami, M. H.; Morris, D. L. Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc. Hematol. Agents Med. Chem., 2008, 6, 343-7.
56. Furuya, M.; Yonemitsu, Y. Cancer neovascularization and proinflammatory microenvironments. Curr. Cancer Drug Targets, 2008, 8, 253-65.
57. Burmester, G. R.; Feist, E.; Kellner, H.; Braun, J.; Iking-Konert, C.; Rubbert-Roth, A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann. Rheum. Dis., 2010.
58. Shinriki, S.; Jono, H.; Ota, K.; Ueda, M.; Kudo, M.; Ota, T.; Oike, Y.; Endo, M.; Ibusuki, M.; Hiraki, A.; Nakayama, H.; Yoshitake, Y.; Shinohara, M.; Ando, Y. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin. Cancer Res., 2009, 15, 5426-34.
59. Nikodemova, M.; Duncan, I. D.; Watters, J. J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J. Neurochem., 2006, 96, 314-23.
60. Blum-Degen, D.; Muller, T.; Kuhn, W.; Gerlach, M.; Przuntek, H.; Riederer, P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett., 1995, 202, 17-20.
61. Kanda, T.; Takahashi, T. Interleukin-6 and cardiovascular diseases. Jpn Heart J., 2004, 45, 183-93.
62. Yin, D. X.; Schimke, R. T. Inhibition of apoptosis by overexpressing Bcl-2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Proc. Natl. Acad. Sci. USA, 1996, 93, 3394-8.
63. Sagar, J.; Sales, K.; Seifalian, A.; Winslet, M. Doxycycline in mitochondrial mediated pathway of apoptosis: a systematic review. Anticancer Agents Med. Chem., 2010, 10, 556-63.
64. Elewa, H. F.; Hilali, H.; Hess, D. C.; Machado, L. S.; Fagan, S. C. Minocycline for short-term neuroprotection. Pharmacotherapy, 2006, 26, 515-21.
65. Zemke, D.; Majid, A. The potential of minocycline for neuroprotection in human neurologic disease. Clin. Neuropharmacol., 2004, 27, 293-8.
66. Choi, Y.; Kim, H. S.; Shin, K. Y.; Kim, E. M.; Kim, M.; Park, C. H.; Jeong, Y. H.; Yoo, J.; Lee, J. P.; Chang, K. A.; Kim, S.; Suh, Y. H. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology, 2007, 32, 2393-404.
67. Tikka, T.; Fiebich, B. L.; Goldsteins, G.; Keinanen, R.; Koistinaho, J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci., 2001, 21, 2580-8.
68. Zhang, P.; Lokuta, K. M.; Turner, D. E.; Liu, B. Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. J. Neurochem., 2010, 112, 434-43.
69. Gieseler, A.; Schultze, A. T.; Kupsch, K.; Haroon, M. F.; Wolf, G.; Siemen, D.; Kreutzmann, P. Inhibitory modulation of the mitochondrial permeability transition by minocycline. Biochem. Pharmacol., 2009, 77, 888-96.
70. Orsucci, D.; Mancuso, M.; Siciliano, G. Mitochondria, oxidative stress and PARP-1 network: a new target for neuroprotective effects of tetracyclines? J. Physiol., 2008, 586, 2427-8.
71. Antonenko, Y. N.; Rokitskaya, T. I.; Cooper, A. J.; Krasnikov, B. F. Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels. J. Bioenerg. Biomembr., 2010, 42, 151-63.
72. Heo, K.; Cho, Y. J.; Cho, K. J.; Kim, H. W.; Kim, H. J.; Shin, H. Y.; Lee, B. I.; Kim, G. W. Minocycline inhibits caspase-dependent and-independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett, 2006, 398, 195-200.
73. Dumont, E. A.; Lutgens, S. P.; Reutelingsperger, C. P.; Bos, G. M.; Hofstra, L. Minocycline inhibits apoptotic cell death in a murine model of partial flap loss. J Reconstr. Microsurg., 2010, 26, 523-8.
74. Chen, M.; Ona, V. O.; Li, M.; Ferrante, R. J.; Fink, K. B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L. A.; Hersch, S. M.; Hobbs, W.; Vonsattel, J. P.; Cha, J. H.; Friedlander, R. M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 2000, 6, 797-801.
75. Scarabelli, T. M.; Stephanou, A.; Pasini, E.; Gitti, G.; Townsend, P.; Lawrence, K.; Chen-Scarabelli, C.; Saravolatz, L.; Latchman, D.; Knight, R.; Gardin, J. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J. Am. Coll. Cardiol., 2004, 43, 865-74.
76. Teng Y.; Choi H.; Onario R.; Zhu S.; Desilets F.; Lan S.; Woodard E.; Snyder E. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. USA., 2004, 101, 3071-76.